Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3376386 | 1.00 | CA2 (0.49) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL4918516 | 1.00 | CA2 (0.49) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL17038984 | 0.84 | CA2 (0.47) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL17038983 | 0.84 | CA2 (0.47) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL2066105 | 0.82 | CA2 (0.46) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL4926340 | 0.82 | CA2 (0.46) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL2066108 | 0.82 | CA2 (0.46) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL9209151 | 0.81 | CA2 (0.36) | CA2TMEM97SIGMAR1KDM4EMAPT | |
| SCHEMBL24500216 | 0.79 | CA2 (0.44) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 | |
| SCHEMBL16448088 | 0.79 | TMEM97 (0.45) | CA2TMEM97SIGMAR1ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699557-B1 | 3-(OXAZOL-2-YL-ETHOXY)- AND 3-(THIAZOL-2-YL-ETHOXY)-BENZAMIDE DERIVATIVES AS ANTI-BACTERIAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2017-08-16 | — | — | EP | disclosed |
| EP-2699557-B1 | 3-(OXAZOL-2-YL-ETHOXY)- AND 3-(THIAZOL-2-YL-ETHOXY)-BENZAMIDE DERIVATIVES AS ANTI-BACTERIAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2017-08-16 | — | — | EP | disclosed |
| US-9511073-B2 | Aromatic amides and uses thereof | TAXIS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511073-B2 | Aromatic amides and uses thereof | TAXIS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511073-B2 | Aromatic amides and uses thereof | TAXIS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20140135332-A1 | AROMATIC AMIDES AND USES THEREOF | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-05-15 | — | — | US | disclosed |
| US-20140135332-A1 | AROMATIC AMIDES AND USES THEREOF | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-05-15 | — | — | US | disclosed |
| US-20140135332-A1 | AROMATIC AMIDES AND USES THEREOF | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2014-05-15 | — | — | US | disclosed |
| EP-2699557-A1 | AROMATIC AMIDES AND USES THEREOF | Biota Scientific Management Pty Ltd (AU) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012142671-A1 | AROMATIC AMIDES AND USES THEREOF | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012142671-A1 | AROMATIC AMIDES AND USES THEREOF | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012007409-A1 | N-SUBSTITUTED PYRROLIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-7390825-B1 | Process for the preparation of oxazolidinones and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080146458-A1 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-06-19 | — | — | US | disclosed |
| US-20070265451-A1 | Process for the preparation of oxazolidinones and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2007-11-15 | — | — | US | disclosed |
| EP-0368429-A2 | Fluor-substituted benzene derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265451-A1 | Process for the preparation of oxazolidinones and method of use thereof | OXA1L, OTC, ODC1 | CA2 2996/4885TMEM97 3426/4885SIGMAR1 1946/4885 |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | MAPK15, MOK, MAPK14 | CA2 4306/4885TMEM97 1809/4885SIGMAR1 3185/4885 |
| US-20080146458-A1 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | OXA1L, OGFOD1, CYP51A1 | CA2 4770/4885TMEM97 2202/4885SIGMAR1 1464/4885 |
| US-20140135332-A1 | AROMATIC AMIDES AND USES THEREOF | NAT1, ASNS, CYP2C9 | CA2 1020/4885TMEM97 4112/4885SIGMAR1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.